Tolerance of the developing cyanotic heart to ischemia-reperfusion injury in the rat

Fujii, Yasuhiro; Ishino, Kozo; Tomii, Tomoko; Kanamitsu, Hitoshi; Mitsui, Hideya; Sano, Shunji

doi:10.1007/s11748-009-0497-y

Cited by 4 publications

(5 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the cause of the diminished cardioprotective effect is unknown, it may result from an overlapping mechanism of both the cardioprotective effect of a NO donor and chronic hypoxia. Chronic hypoxia has a cardioprotective effect against subsequent global ischemia (5,6); this effect is mediated by the activation of NO production and subsequent myocardial cGMP synthesis (4,6,7). Replicating the same cardioprotective effect may be of no benefit and may even be harmful.…”

mentioning

confidence: 99%

Atrionatriuretic Peptide Improves Left Ventricular Function After Myocardial Global Ischemia–Reperfusion in Hypoxic Hearts

et al. 2011

Self Cite

View full text Add to dashboard Cite

Atrionatriuretic peptide (ANP) is reported to be useful for attenuating myocardial ischemia-reperfusion injury and improving left ventricular function after reperfusion. However, ANP may be either ineffectual or harmful in cases where the myocardium has been chronically hypoxic since birth. This can be a result of the concomitant high levels of cyclic guanosine monophosphate (cGMP) produced within the myocardium. This study aimed to verify the validity of using ANP to improve left ventricular function after myocardial ischemia-reperfusion injury. For this purpose, a cyanotic congenital disease model that was developed using isolated rat hearts was used. Hearts were obtained from Sprague-Dawley rats that were housed from birth until 6 weeks of age either in a hypoxic environment with 13-14% FiO(2) (hypoxic group) or in ambient air (normoxic group). These hearts were subjected to 30min of normothermic global ischemia followed by 30min of reperfusion using the Langendorff technique. Left ventricular functional recovery in hearts administered ANP (0.1µM) into the reperfusion solution was compared with those hearts that were not administered ANP in both hypoxic (without ANP: n=6, with ANP: n=6, with ANP and HS-142-1[an antagonist of ANP]: n=6) and normoxic hearts (without ANP: n =6, with ANP: n=6). In the hypoxic hearts, ANP administration improved the percent recovery of the left ventricular developed pressure (76.3±9.2% without ANP vs. 86.9±6.7% with ANP), maximum first derivative of the left ventricular pressure (82.4±1.1% without ANP vs. 95.8±6.5% with ANP), and heart rate (85.6±4.7% without ANP vs. 96.1±5.2% with ANP) after reperfusion. The improvement and recovery of these cardiac functions were closely related to significantly increased levels of postischemic cGMP release after ANP administration. The effect of ANP was blocked by HS-142-1. The improvements observed in the hypoxic group were similar to those found in the normoxic group. ANP administration during reperfusion improved left ventricular function after myocardial acute global ischemia-reperfusion equally in both the chronically hypoxic and age-matched normoxic groups.

show abstract

mentioning

confidence: 99%

Atrionatriuretic Peptide Improves Left Ventricular Function After Myocardial Global Ischemia–Reperfusion in Hypoxic Hearts

et al. 2011

Self Cite

View full text Add to dashboard Cite

show abstract

“…Previous studies have demonstrated that CIH confers long-lasting cardioprotection against acute I/R injury ( 7 , 10 , 26 ). Furthermore, clinical observations and epidemiological studies have implicated CIH in cardioprotection ( 2 ).…”

Section: Discussionmentioning

confidence: 99%

Upregulated ATF6 contributes to chronic intermittent hypoxia-afforded protection against myocardial ischemia/reperfusion injury

Jia

Zhao

et al. 2016

International Journal of Molecular Medicine

View full text Add to dashboard Cite

In the present study, we investigated the role of activating transcription factor 6 (ATF6) in the mechanism by which chronic intermittent hypoxia (CIH) increases tolerance to myocardial ischemia/reperfusion (I/R). Experiments were conducted using a rat model of I/R injury in vivo and isolated Langendorff-perfused rat hearts ex vivo. The role of Akt in this process was also investigated in vitro using rat myoblast H9c2 cells. Cell viability was measured using a cell counting kit-8 assay. Lactate dehydrogenase (LDH) and creatine kinase cardiac isoenzyme activity were also measured as markers of cellular damage. ATF6, Akt and phosphorylated (p)-Akt expression was analyzed by western blot analysis. RNA interference (RNAi) was used to suppress ATF6 expression. We noted that ATF6 expression in the ventricular myocardium was significantly increased in rats exposed to CIH. Furthermore, we noted that CIH preserved cardiac function after I/R in vivo and improved post-ischemic recovery of myocardial performance in isolated rat hearts. ATF6 and p-Akt expression was upregulated in cultured H9c2 cells exposed to chronic mild hypoxia compared with those cultured under normoxic conditions. Chronic mild hypoxia attenuated subsequent simulated I/R injury in H9c2 cells (48 h), as evidenced by increased cell viability and decreased LDH activity. By contrast, decreased cell viability and increased LDH activity were observed in siRNA-ATF6-transfected H9c2 cells, with a concomitant reduction in p-Akt levels. These results indicated that ATF6 upregulation is involved in the mechanism by which CIH attenuates myocardial I/R injury, possibly through upregulation of p-Akt, which is a key regulator of cardiomyocyte survival.

show abstract

“…The glycogen granules were recruited as an energy substrate and used to produce ATP in the case of hypoxia . In Fujii's study , it was revealed that the hearts from cyanotic rats had a higher cyclic GMP than the heats from noncyanotic rats. The higher cyclic GMP might give rise to anerobic glycolysis in response to hypoxia; it was the reason why the cyanotic rats had the greater tolerance to ischemia.…”

Section: Discussionmentioning

confidence: 99%

Clinical Assessment of Histidine‐Tryptophan‐Ketoglutarate Solution and Modified St. Thomas' Solution in Pediatric Cardiac Surgery of Tetralogy of Fallot

Wang

An²,

Mingcheng³

et al. 2016

Artificial Organs

View full text Add to dashboard Cite

The objective of this study is to compare the myocardium protective effect of Bretschneider's histidine-tryptophan-ketoglutarate (HTK) solution versus Modified St. Thomas' (STH) solution in pediatric cardiac surgery of Tetralogy of Fallot (TOF). Seventy-seven pediatric patients of TOF who received the total surgical repair were reviewed, from January 2014 to October 2015. A horizontal comparison between HTK solution and modified STH solution has been made since the HTK solutions were started to be used in our hospital. The patients were divided into the HTK group (n = 35) and the STH group (n = 33). The perioperative values of the groups were assessed in this study. The primary endpoints including spontaneous cardiac re-beating time, intensive care unit (ICU) stay, overall stay, mechanical ventilation postoperation, postoperation stay, overall stay, and perioperative echocardiographic results were analyzed in this study. We found that spontaneous cardiac re-beating time of the HTK group was significantly shorter than that of the STH group (0.26 min ± 0.56 vs. 1.33 ± 1.02, P < 0.001). There were no significant differences between the two groups in ICU stay (P = 0.29), postoperative mechanical ventilation time (P = 0.84), overall stay (0.73); and the mortalities of the two groups were similar (2.9 vs. 3.0%). Aimed at pediatric cardiac surgery of TOF, this study suggests that with similar aorta cross-clamping time, modified STH solution is as safe as HTK solution.

show abstract

Tolerance of the developing cyanotic heart to ischemia-reperfusion injury in the rat

Abstract: Chronic hypoxia from birth increased myocardial tolerance to ischemia-reperfusion injury with increased cGMP synthesis in the isolated heart model in rats.

Cited by 4 publications

References 29 publications

Atrionatriuretic Peptide Improves Left Ventricular Function After Myocardial Global Ischemia–Reperfusion in Hypoxic Hearts

Atrionatriuretic Peptide Improves Left Ventricular Function After Myocardial Global Ischemia–Reperfusion in Hypoxic Hearts

Upregulated ATF6 contributes to chronic intermittent hypoxia-afforded protection against myocardial ischemia/reperfusion injury

Clinical Assessment of Histidine‐Tryptophan‐Ketoglutarate Solution and Modified St. Thomas' Solution in Pediatric Cardiac Surgery of Tetralogy of Fallot

Contact Info

Product

Resources

About